• Accueil
• tpex
• Figure 5 from Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

Figure 5 from Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

5 (524) · € 24.00 · En Stock

Fig. 5. Overall survival comparing TPEx regimen and EXTREME regimen - "Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting"

Lung Cancer Research Highlights from the 2019 ASCO Annual Meeting

HR+/HER2- Advanced breast cancer: what are the latest developments

2022 ASCO® Annual Meeting: Updates on the Treatment of Advanced

PRISMA diagram of eligible studies. ASCO, American Society of

ASCO 2022: Equity, innovation and in-person

Interobserver Variation in the Assessment of Immunohistochemistry

ASCO Annual Meeting 2019 Highlights

Mitigating long-term and delayed adverse events associated with

Optimizing frontline immunotherapy for advanced NSCLC - touchONCOLOGY

Korean Journal of Head & Neck Oncology

2019 Annual Report - University of Chicago Medicine Comprehensive